RxDoctor Payments Data

Neeta Pandit-Taskar, MD

Nuclear Medicine · Pittsburgh, PANPI 1871570010

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $50,138 of the $59,559 with a category attached, or 84.2%. 8 manufacturers reported payments, led by Regeneron at 55.0% of the total. 2025 is the largest year on record at $45,590, more than ten times the $2,838 reported in 2019. Among nuclear medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,559in general payments, 2019–2025

Across 51 payments — averaging $1167.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$33K
  • Telix Pharmaceuticals$8K
  • Blue Earth Diagnostics$8K
  • Progenics Pharmaceuticals, Inc.$6K
  • Astrazeneca UK Limited$5K
  • AstraZeneca$976
  • plus $60 from 2 others
$285,945in research payments, 2019–2025

Across 9 payments — averaging $31,772 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$282K
  • Biontech SE$4K

What the payments were for

  • Consulting fees$50,13884%
  • Speaking & faculty fees$2,0003%
  • Travel & lodging$5,3419%
  • Food & beverage$2,0803%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,559 in reported general payments places this provider in the 95th percentile of 25 nuclear medicine providers in Pennsylvania.

See all nuclear medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,883
Medicare patients
1,432
Services billed
1,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →